The field of targeted therapeutics has been energized by the clinical demonstration of significant response rates and verified clinical benefit in patients with HER2/neu-positive breast cancer treated with Kadcyla in numerous clinical trials [52]. This evidence concerns the gene ERBB2 and breast carcinoma.